Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 7/20 | 0.60 |
| ▸ | ACE | P12821 | 6/20 | 0.60 |
| ▸ | CPA1 | P15085 | 6/20 | 0.60 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.60 |
| ▸ | GNPAT | O15228 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 7/20 | 0.48 |
| ▸ | MMP1 | P03956 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9955555 | 1.00 | MME (0.60) | MMEACECPA1ACE2GNPAT | |
| SCHEMBL1477244 | 0.93 | MME (0.54) | MMEACECPA1ACE2GNPAT | |
| SCHEMBL8727951 | 0.93 | MME (0.54) | MMEACECPA1ACE2GNPAT | |
| SCHEMBL6565110 | 0.90 | GNPAT (0.53) | MMEACECPA1ACE2GNPAT | |
| SCHEMBL7033970 | 0.88 | NPY4R (0.57) | MMEACECPA1ACE2 | |
| SCHEMBL30555017 | 0.85 | MME (0.60) | MMEACECPA1ACE2GNPAT | |
| SCHEMBL8213821 | 0.85 | NPY4R (0.56) | MMEACE | |
| SCHEMBL8213819 | 0.85 | NPY4R (0.56) | MMEACE | |
| SCHEMBL28249173 | 0.84 | MME (0.57) | MMEACECPA1ACE2GNPAT | |
| SCHEMBL3382813 | 0.84 | LTA4H (0.58) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618790-B2 | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20200207874-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | HOFFMANN-LA ROCHE INC. (US) | 2020-07-02 | — | — | US | disclosed |
| EP-2655413-B1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | HOFFMANN LA ROCHE (CH) | 2019-01-16 | — | — | EP | disclosed |
| EP-2867255-B1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | disclosed |
| US-20150232560-A1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2015-08-20 | — | — | US | disclosed |
| EP-2867255-A1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014001326-A1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| US-20130344094-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-26 | — | — | US | disclosed |
| EP-2655413-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085111-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130344094-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | PNKP, RNASE1, DCLRE1B | MME 176/4885ACE 3178/4885CPA1 266/4885 |
| US-20150232560-A1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | FCGR3B, VSIG8, CD47 | MME 259/4885ACE 4325/4885CPA1 1861/4885 |
| US-20200207874-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | PNKP, RNASE1, DCLRE1B | MME 176/4885ACE 3178/4885CPA1 266/4885 |
| US-11618790-B2 | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery | PNKP, RNASE1, DCLRE1B | MME 176/4885ACE 3178/4885CPA1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.